Updated:
Longevity Capital
Longevity Capital is a family office deploying capital exclusively into geroscience and aging biology biotech companies targeting human healthspan...
Longevity Capital
Longevity Capital functions as a privately held investment entity focused on the science of longevity. The firm commits capital to early and growth-stage biotechnology companies advancing therapies grounded in the biology of aging, covering modalities such as small molecules, gene therapies, and epigenetic reprogramming. Investment activity concentrates on companies targeting core hallmarks of aging, including cellular senescence, mitochondrial dysfunction, and stem cell exhaustion. The geographic footprint includes investments in North American and European biotechnology hubs. The firm structures its deployment primarily as direct equity investments and selectively participates in venture rounds led by specialist life science venture capital firms. Longevity Capital has participated in funding rounds for companies including Unity Biotechnology, a developer of senolytic medicines, and Cambrian Biopharma, a distributed development company building a pipeline of therapies targeting multiple aging pathways. The firm maintains relationships with co-investors such as ARCH Venture Partners and Longitude Capital. Longevity Capital operates without publicly disclosed team size, portfolio value, or aggregate capital commitments. The firm's operational model relies on combining principal capital with the scientific networks of key opinion leaders in geroscience. No adjacent philanthropic foundations or operating subsidiaries have been publicly disclosed under the Longevity Capital name. Longevity Capital's structure aligns principal capital with a pre-paradigm investment thesis that most institutional allocators treat as too narrow or unproven. The firm does not diversify into general healthcare or standard biotech—it exclusively backs interventions that target the biology of aging itself. This technical concentration means the firm competes more often with aging-focused venture studios and specialist research foundations than with typical multi-asset family offices, creating a sourcing model that relies on deep academic networks and clinical-stage translation timing.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Longevity Capital's specific investment thesis?
Longevity Capital invests exclusively in companies developing therapeutics that target the fundamental biology of aging. Rather than focusing on a single disease area, the firm backs platforms capable of addressing multiple age-related conditions by intervening in core aging mechanisms such as cellular senescence, epigenetic alteration, and mitochondrial decline. This approach to geroscience positions the portfolio for indications ranging from osteoarthritis to neurodegenerative diseases under a unified biological framework.
Does Longevity Capital invest through funds or only directly?
Longevity Capital structures its deployment as direct equity investments in biotechnology companies, participating in venture rounds alongside specialist life science fund managers. The firm also selectively engages in distributed development models, where a parent company incubates multiple subsidiary programs against distinct aging pathways. Longevity Capital does not publicly operate as a fund-of-funds or open its own vehicles to external limited partners.
Which biotech companies has Longevity Capital backed?
Public records and trade publication reporting identify Longevity Capital as a participant in funding rounds for Unity Biotechnology, a company developing senolytic medicines to clear senescent cells, and Cambrian Biopharma, a holding company structure that builds multiple subsidiary programs targeting different hallmarks of aging. Both investments place the firm squarely within the translational geroscience sector, backing human clinical-stage programs rather than preclinical longevity platforms.
How does Longevity Capital source its deals?
Longevity Capital's deal flow originates from its scientific networks within academic geroscience and the broader aging biology research community. The firm co-invests alongside specialist venture firms including ARCH Venture Partners and Longitude Capital, leveraging those relationships for diligence and access. This academic-venture hybrid sourcing model differs from generalist family offices that rely on placement agents or wealth management platforms for biotech exposure.
Is Longevity Capital a single-family office or another structure?
Based on its investment activity and operating posture, Longevity Capital operates as a principal investment entity consistent with a single-family office structure, deploying proprietary capital rather than managing third-party funds. The firm does not publicly market itself as a multi-family office, registered investment advisor, or venture capital fund manager, and no external fundraising activity has been reported.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: